Adopting a computational approach for the assessment of urine cytology specimens has the potential to improve the efficiency, accuracy and reliability of bladder cancer screening, which has heretofore relied on semi-subjective manual assessment methods. As rigorous, quantitative criteria and guidelines have been introduced for improving screening practices, e.g., The Paris System for Reporting Urinary Cytology (TPS), algorithms to emulate semi-autonomous diagnostic decision-making have lagged behind, in part due to the complex and nuanced nature of urine cytology reporting. In this study, we report on a deep learning tool, AutoParis-X, which can facilitate rapid semi-autonomous examination of urine cytology specimens. Through a large-scale retrospective validation study, results indicate that AutoParis-X can accurately determine urothelial cell atypia and aggregate a wide-variety of cell and cluster-related information across a slide to yield an Atypia Burden Score (ABS) that correlates closely with overall specimen atypia, predictive of TPS diagnostic categories. Importantly, this approach accounts for challenges associated with assessment of overlapping cell cluster borders, which improved the ability to predict specimen atypia and accurately estimate the nuclear-to-cytoplasm (NC) ratio for cells in these clusters. We developed an interactive web application that is publicly available and open-source, which features a simple, easy-to-use display for examining urine cytology whole-slide images (WSI) and determining the atypia level of specific cells, flagging the most abnormal cells for pathologist review. The accuracy of AutoParis-X (and other semi-automated digital pathology systems) indicates that these technologies are approaching clinical readiness and necessitates full evaluation of these algorithms via head-to-head clinical trials.

The authors have declared no competing interest.

JL is funded under NIH subawards P20GM130454 and P20GM104416.

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

Human Research Protection Program IRB of Dartmouth Health gave ethical approval for this work.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes

Access to manuscript data is limited due to patient privacy concerns. Data produced in the present study are available upon reasonable request to the authors and four specimens are made available for demonstrated assessment at the following URL: http://edit.autoparis.demo.levylab.host.dartmouth.edu/

http://edit.autoparis.demo.levylab.host.dartmouth.edu/